Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.68 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.68 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.67 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.64 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.62 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.60 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10454900 | 0.99 | P2RY1 (0.67) | P2RY1P2RX3P2RX4ENPP1P2RX1 | |
| SCHEMBL2513837 | 0.97 | P2RY1 (0.67) | P2RY1P2RX3P2RX4ENPP1P2RX1 | |
| Triphosphate SCHEMBL11811171 | 0.95 | CA5A (0.64) | P2RY1P2RX3P2RX4ENPP1P2RX1 | |
| Guanosine Triphosphate SCHEMBL15900104 | 0.92 | P2RY1 (0.70) | P2RY1P2RX3P2RX4ENPP1P2RX1 | |
| Gtp SCHEMBL15900105 | 0.92 | P2RY1 (0.70) | P2RY1P2RX3P2RX4ENPP1P2RX1 | |
| SCHEMBL188740 | 0.91 | CA5A (0.68) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| SCHEMBL1904678 | 0.90 | P2RY1 (0.66) | P2RY1P2RX3P2RX4ENPP1P2RX1 | |
| SCHEMBL15794408 | 0.90 | P2RY1 (0.79) | P2RY1P2RX3P2RX4ENPP1P2RX1 | |
| Ammonia Solution, Strong SCHEMBL4362929 | 0.90 | CA5A (0.67) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| SCHEMBL1902605 | 0.89 | P2RY1 (0.65) | P2RY1P2RX3P2RX4ENPP1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | CureVac SE (DE) | 2025-11-04 | — | — | US | claimed |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| EP-4403042-A2 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2024-07-24 | — | — | EP | claimed |
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20230096781-A1 | METHODS OF CONTROLLING BODYWEIGHT BY MODULATING PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE BETA ACTIVITY | UNIVERSITY OF CINCINNATI (US) | 2023-03-30 | — | — | US | claimed |
| EP-4114963-A1 | METHODS OF CONTROLLING BODYWEIGHT BY MODULATING PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE BETA ACTIVITY | University of Cincinnati (US) | 2023-01-11 | — | — | EP | claimed |
| US-20220372158-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2022-11-24 | — | — | US | claimed |
| US-11421038-B2 | RNA-coded antibody | CUREVAC AG (DE) | 2022-08-23 | — | — | US | claimed |
| US-20220145295-A1 | ENZYMATIC RNA SYNTHESIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-12 | — | — | US | claimed |
| US-20150184195-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES | CUREVAC GMBH (DE) | 2015-07-02 | — | — | US | claimed |
| US-20150165006-A1 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED ALLERGENIC ANTIGEN OR AN AUTOIMMUNE SELF-ANTIGEN | Cure GmbH (DE) | 2015-06-18 | — | — | US | claimed |
| US-20150093413-A1 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN | CUREVAC GMBH (DE) | 2015-04-02 | — | — | US | claimed |
| US-20140170689-A1 | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-06-19 | — | — | US | claimed |
| US-20130195867-A1 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| US-20100189729-A1 | RNA-CODED ANTIBODY | CURVAC GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20100047261-A1 | BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2010-02-25 | — | — | US | claimed |
| EP-2083851-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | Curevac GmbH (DE) | 2009-08-05 | — | — | EP | claimed |
| WO-2008052770-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2008-05-08 | — | — | WO | claimed |
| US-5902793-A | ADMINISTERING TO MAMMAL GAMMA-MONOALKYL- OR GAMMA-ALKENYL-NUCLEOSIDE OR DEOXYNUCLEOSIDE TRIPHOSPHATE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-05-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150093413-A1 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN | HNRNPH3, PARG, CPSF6 | P2RY1 1936/4885P2RX3 1754/4885P2RX4 2530/4885 |
| US-20150165006-A1 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED ALLERGENIC ANTIGEN OR AN AUTOIMMUNE SELF-ANTIGEN | NASP, H1-5, PARG | P2RY1 1538/4885P2RX3 1492/4885P2RX4 2095/4885 |
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | RNMT, NSUN3, RNGTT | P2RY1 2831/4885P2RX3 2043/4885P2RX4 2732/4885 |
| US-20100047261-A1 | BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | RNMT, RNASE1, NSUN3 | P2RY1 4557/4885P2RX3 4449/4885P2RX4 4744/4885 |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY1 3509/4885P2RX3 2826/4885P2RX4 4000/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY1 3509/4885P2RX3 2826/4885P2RX4 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.